Clinical practice guidelines for the administration of third-generation anti-seizure medications

作者：Xintong Wu, Yangmei Chen, Feng Li, Xiong Han, Yanbing Han, Huapin Huang, Qifu Li, Xiao‐Rong Liu, Liankun Ren, Yanping Sun, Qun Wang, Tiancheng Wang, Xiangqing Wang, Bo Xiao, Huiqin Xu, Peimin Yu, Hong Zhang, Guoxing Zhu, Suiqiang Zhu, Dong Zhou · 发表于：Seizure · 年份：2025 · DOI：10.1016/j.seizure.2025.11.002 · 被引用次数：2 · 研究领域：Epilepsy research and treatment、Amyotrophic Lateral Sclerosis Research、Neurological disorders and treatments

PURPOSE: This guideline evaluated previous clinical studies that examined the use of third-generation antiseizure medications (ASMs) to treat epilepsy in order to provide treatment recommendations from a clinical practice perspective, thus aiming to enhance clinicians' understanding of these drugs and improve the standardization of clinical treatment. METHODS: A systematic literature search was conducted to identify studies that examined third-generation ASMs. The included literature was rated using the 2011 Oxford Centre for Evidence-based Medicine (OCEBM) levels of evidence, and recommendations were formulated. The strength of the recommendations was determined based on the evidence level and drug safety profiles. RESULTS: This guideline examines 10 third-generation ASMs: pregabalin (PGB), rufamide (RFN), lacosamide (LCM), perampanel (PER), eslicarbazepine (ESL), brivaracetam (BRV), stripentol (STP), cannabidiol (CBD), cenobamate (CNB) and fenfluramine (FFA). Recommendations were developed for 13 clinical questions. CONCLUSION: This guideline provides a detailed evaluation of the current evidence and treatment recommendations regarding third-generation ASMs. This guideline will help clinicians to better understand these medications and offer guidance for clinical practice.